Search research articles
Contact Us
Filters
Showing results (1-10 of 9) with videos related to
Page
of 1
Sort By:
Drug Safety
|
August 28, 2001
Manufacturer's drug interaction and postmarketing adverse event data: what are appropriate uses?
W K Kraft, S A Waldman
Clinical Pharmacology and Therapeutics
|
May 22, 2012
Healthy volunteer registries and ethical research principles
E A Kupetsky-Rincon, W K Kraft
Clinical Pharmacology and Therapeutics
|
May 6, 2017
The Nephrotoxicity of Vancomycin
E J Filippone, W K Kraft, J L Farber
Seminars in Fetal & Neonatal Medicine
|
February 13, 2019
Pharmacological and non-pharmacological treatments for the Neonatal Abstinence Syndrome (NAS)
A K Mangat, G M Schmölzer, W K Kraft
Journal of Perinatology : Official Journal of the California Perinatal Association
|
February 21, 2020
Development of an abbreviated symptom score for the neonatal abstinence syndrome
I Chervoneva, S C Adeniyi-Jones, F Blanco, et al.
Clinical and Translational Science
|
May 13, 2016
Reversibility of Apixaban Anticoagulation with a Four-Factor Prothrombin Complex Concentrate in Healthy Volunteers
S Nagalla, L Thomson, Y Oppong, et al.
International Journal of Clinical Pharmacology and Therapeutics
|
April 10, 2007
Transgenic avian-derived recombinant human interferon-alpha2b (AVI-005) in healthy subjects: an open-label, single-dose, controlled study
T B Patel, E Pequignot, S H Parker, et al.
CPT: Pharmacometrics & Systems Pharmacology
|
September 18, 2016
A Population Pharmacokinetic Model for Vancomycin in Adult Patients Receiving Extracorporeal Membrane Oxygenation Therapy
J N Moore, J R Healy, B N Thoma, et al.
Clinical and Translational Science
|
June 16, 2016
Effect of Vorapaxar Alone and in Combination with Aspirin on Bleeding Time and Platelet Aggregation in Healthy Adult Subjects
W K Kraft, J H Gilmartin, D L Chappell, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 9) with videos related to
Sort By:
Page
of 1
Drug Safety
|
August 28, 2001
Manufacturer's drug interaction and postmarketing adverse event data: what are appropriate uses?
W K Kraft, S A Waldman
Clinical Pharmacology and Therapeutics
|
May 22, 2012
Healthy volunteer registries and ethical research principles
E A Kupetsky-Rincon, W K Kraft
Clinical Pharmacology and Therapeutics
|
May 6, 2017
The Nephrotoxicity of Vancomycin
E J Filippone, W K Kraft, J L Farber
Seminars in Fetal & Neonatal Medicine
|
February 13, 2019
Pharmacological and non-pharmacological treatments for the Neonatal Abstinence Syndrome (NAS)
A K Mangat, G M Schmölzer, W K Kraft
Journal of Perinatology : Official Journal of the California Perinatal Association
|
February 21, 2020
Development of an abbreviated symptom score for the neonatal abstinence syndrome
I Chervoneva, S C Adeniyi-Jones, F Blanco, et al.
Clinical and Translational Science
|
May 13, 2016
Reversibility of Apixaban Anticoagulation with a Four-Factor Prothrombin Complex Concentrate in Healthy Volunteers
S Nagalla, L Thomson, Y Oppong, et al.
International Journal of Clinical Pharmacology and Therapeutics
|
April 10, 2007
Transgenic avian-derived recombinant human interferon-alpha2b (AVI-005) in healthy subjects: an open-label, single-dose, controlled study
T B Patel, E Pequignot, S H Parker, et al.
CPT: Pharmacometrics & Systems Pharmacology
|
September 18, 2016
A Population Pharmacokinetic Model for Vancomycin in Adult Patients Receiving Extracorporeal Membrane Oxygenation Therapy
J N Moore, J R Healy, B N Thoma, et al.
Clinical and Translational Science
|
June 16, 2016
Effect of Vorapaxar Alone and in Combination with Aspirin on Bleeding Time and Platelet Aggregation in Healthy Adult Subjects
W K Kraft, J H Gilmartin, D L Chappell, et al.
Page
of 1